tbuckley/cabot-search huggingface dataset:
Mannose Labeled Liposome Containing DXR Administration Is Effective in Reversing Thrombocytopenia in the Model Mouse of Immune Thrombocytopenia.
Authors: Yoji Ishida, Kazunori Murai, Tatsuo Oyake, Shugo Kowata, Shigeki Ito, Ryo Suzuki, Kazuo Maruyama
Journal: Blood (2007)
HYPOXIA-INDUCIBLE FACTOR 2 Alpha REGULATES NEUTROPHILIC INFLAMMATION IN HUMANS, MICE AND ZEBRAFISH
Authors: Thompson Aar., P M Elks, H M Marriott, K R Higgins, S Parmar, G Shaw, S Eamsamarng, E E McGrath, F Formenti, F J Van Eeden, V L Kinnula, C W Pugh, I Sabroe, D H Dockrell, E R Chilvers, P A Robbins, M C Simon, R S Johnson, S A Renshaw, Whyte Mkb., Walmsley
Journal: Thorax (2012)
Results of a nationally implemented de novo cardiac screening programme in elite rugby players in England
Authors: Saqib Ghani, Michael Papadakis, Simon Kemp, Abbas Zaidi, Nabeel Sheikh, Sabiha Gati, Hariharan Raju, Andy Smith, Corin Palmer, John Somauroo, Sanjay Sharma
Journal: British Journal of Sports Medicine (2016)

Screening of young competitive athletes remains a contentious issue. In 2010, a nationwide cardiac screening for all elite rugby players was introduced in England. This provided a unique opportunity to prospectively assess the feasibility and cost-effectiveness of a de novo, ECG-based cardiac screening programme.Between 2010 and 2012, 1191 rugby players aged ≥14 years underwent cardiac screening with a health questionnaire, 12-lead ECG and a consultation with a cardiologist. The players with concerning findings on initial evaluation were offered on-site transthoracic echocardiogram (TTE). Athletes were referred for further investigations as deemed necessary. The overall cost of the screening programme was estimated.After initial evaluation, 9.7% of athletes underwent on-site TTE; 8.2% underwent on-site TTE due to ECG anomalies and 1.4% underwent on-site TTE due to concerns on the questionnaire. After TTE, only 2.9% of the total cohort was referred for further evaluation. Two players were diagnosed with potentially serious conditions; one with Wolff-Parkinson-White, who resumed competition after catheter ablation, and one with hypertrophic cardiomyopathy, who withdrew from competition. During a mean follow-up of 52.8±5.5 months, none of the players who were reassured experienced any adverse cardiac events. The total cost of the screening programme was £59 875, which averaged to a cost of £50 per player or £29 938 per condition identified. Application of refined ECG criteria would reduce the ECG false-positive rate to 4.9%.Preparticipation cardiac screening with 12-lead ECG is feasible. Refinement of the ECG criteria, the use of on-site TTE and expert setting can minimise the burden of unnecessary investigations and reduce costs.
Increase of Total Nephron Albumin Filtration and Reabsorption in Diabetic Nephropathy
Authors: Keita P. Mori, Hideki Yokoi, Masato Kasahara, Hirotaka Imamaki, Akira Ishii, Takashige Kuwabara, Kenichi Koga, Yukiko Kato, Naohiro Toda, Shoko Ohno, Koichiro Kuwahara, Tomomi Endo, Kazuwa Nakao, Motoko Yanagita, Masashi Mukoyama, Kiyoshi Mori
Journal: Journal of the American Society of Nephrology (2016)

The amount of albumin filtered through the glomeruli and reabsorbed at the proximal tubules in normal and in diabetic kidneys is debated. The megalin/cubilin complex mediates protein reabsorption, but genetic knockout of megalin is perinatally lethal. To overcome current technical problems, we generated a drug-inducible megalin-knockout mouse line, megalin(lox/lox);Ndrg1-CreERT2 (iMegKO), in which megalin expression can be shut off at any time by administration of tamoxifen (Tam). Tam administration in adult iMegKO mice decreased the expression of renal megalin protein by 92% compared with that in wild-type C57BL/6J mice and almost completely abrogated renal reabsorption of intravenously injected retinol-binding protein. Furthermore, urinary albumin excretion increased to 175 μg/d (0.46 mg albumin/mg creatinine) in Tam-treated iMegKO mice, suggesting that this was the amount of total nephron albumin filtration. By comparing Tam-treated, streptozotocin-induced diabetic iMegKO mice with Tam-treated nondiabetic iMegKO mice, we estimated that the development of diabetes led to a 1.9-fold increase in total nephron albumin filtration, a 1.8-fold increase in reabsorption, and a significant reduction in reabsorption efficiency (86% efficiency versus 96% efficiency in nondiabetic mice). Insulin treatment normalized these abnormalities. Akita;iMegKO mice, another model of type 1 diabetes, showed equivalent results. Finally, nondiabetic iMegKO mice had a glomerular sieving coefficient of albumin of 1.7×10-5, which approximately doubled in diabetic iMegKO mice. This study reveals actual values and changes of albumin filtration and reabsorption in early diabetic nephropathy in mice, bringing new insights to our understanding of renal albumin dynamics associated with the hyperfiltration status of diabetic nephropathy.
Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
Authors: John H. Sampson, Gordana Vlahovic, Solmaz Sahebjam, Antonio Marcilio Padula Omuro, Joachim M. Baehring, David A Hafler, Alfredo Daniel Voloschin, Prashni Paliwal, Joseph Grosso, Vlad Coric, Timothy F. Cloughesy, Michael Lim, David A. Reardon
Journal: Journal of Clinical Oncology (2015)

3010 Background: GBM has a grim prognosis despite current first-line therapies. Immune checkpoint inhibitors have shown antitumor activity in both solid tumors and preclinical glioma models. This study evaluates the safety/tolerability of the checkpoint inhibitors nivolumab (NIVO) and ipilimumab (IPI) in patients (pts) with a first recurrence of GBM. Methods: Pts were randomized to NIVO 3 mg/kg Q2W or NIVO 1 mg/kg + IPI 3 mg/kg (NIVO+IPI) Q3W followed by NIVO 3 mg/kg Q2W. Eligible pts had first recurrence of primary GBM, no prior bevacizumab treatment and KPS ≥70. The primary endpoint was safety/tolerability. This analysis reports the preliminary experience after all pts had the opportunity to complete ≥6 months (mo) of follow-up after first dose. Results: 20 pts were treated, 10 in each arm. All pts had prior surgical resection, radiation, and temozolomide. Median age was 57 years (range: 37-73), KPS=90 (n=13), 80 (n=2) and 70 (n=5). Median time from first GBM diagnosis was 9 mo. The median number of doses (range) received in NIVO arm was 6 (3-23). In NIVO+IPI, pts received 3 (2-8) doses of NIVO and 2 (2-4) of IPI. Drug-related adverse events (AE) in ≥3 pts were fatigue (n=3) and nausea (n=3) with NIVO and fatigue (n = 8), diarrhea (n = 7), AST and lipase increased (n = 5 each), vomiting and ALT increased (n=4 each), and amylase increased, headache, hyperthyroidism, nausea and maculo-papular rash (n=3 each) with NIVO+IPI. All NIVO AEs were grade 1 or 2. Eight (80%) NIVO+IPI pts had grade 3 or 4 AEs. Drug-related AEs leading to discontinuation occurred only in NIVO+IPI pts (n = 5; 50%), including colitis, cholecystitis, diabetic ketoacidosis, confusion, and increased lipase. There were no drug-related deaths. Among 20 treated pts, OS at 6 mo. was 75%, including 7/10 NIVO pts (70%) and 8/10 NIVO+IPI pts (80%). ORR, PFS, and biomarker analysis are being evaluated. Conclusions: This is the first randomized study to report the safety/tolerability of checkpoint inhibitors in GBM. The AE profile of NIVO ± IPI was consistent with studies in other tumors. OS at 6 mo. is encouraging relative to comparable historical controls. Updated safety, efficacy, and biomarker data including on-treatment histopathology will be presented. Clinical trial information: NCT02017717.
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Authors: Johann S. de Bono, Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Eric J. Small, Neal D. Shore, Karim Fizazi, Peter De Porre, Thian Kheoh, Jinhui Li, Mary B. Todd, Charles J. Ryan, Thomas W. Flaig
Journal: European Urology (2016)

Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve men with mCRPC), abiraterone acetate plus prednisone (AA) significantly improved radiographic progression-free survival and overall survival (OS) when compared to placebo plus prednisone (P). This post hoc analysis investigated clinical responses to docetaxel as first subsequent therapy (FST) among patients who progressed following protocol-specified treatment with AA, and characterized subsequent treatment patterns among older (≥75 yr) and younger (<75 yr) patient subgroups. Data were collected at the final OS analysis (96% of expected death events). Subsequent therapy data were prospectively collected, while response and discontinuation data were collected retrospectively following discontinuation of the study drug. At the discretion of the investigator, 67% (365/546) of patients from the AA arm received subsequent treatment with one or more agents approved for mCRPC. Efficacy analysis was performed for patients for whom baseline and at least one post-baseline prostate-specific antigen (PSA) values were available. Baseline and at least one post-baseline PSA values were available for 100 AA patients who received docetaxel as FST. While acknowledging the limitations of post hoc analyses, 40% (40/100) of these patients had an unconfirmed ≥50% PSA decline with first subsequent docetaxel therapy, and 27% (27/100) had a confirmed ≥50% PSA decline. The median docetaxel treatment duration among these 100 patients was 4.2 mo. Docetaxel was the most common FST among older and younger patients from each treatment arm. However, 43% (79/185) of older patients who progressed on AA received no subsequent therapy for mCRPC, compared with 17% (60/361) of younger patients. Patients with mCRPC who progress with AA treatment may still derive benefit from subsequent docetaxel therapy. These data support further assessment of treatment patterns following AA treatment for mCRPC, particularly among older patients. ClinicalTrials.gov NCT00887198. Treatment patterns for advanced prostate cancer have changed substantially in the last few years. This additional analysis provides evidence of clinical benefit for subsequent chemotherapy in men with advanced prostate cancer whose disease progressed after treatment with abiraterone acetate. Older patients were less likely to be treated with subsequent therapy.
Cartesian Reductionism and Cancer
Authors: H Rubin
Journal: JNCI Journal of the National Cancer Institute (1982)

Cartesian Reductionism and Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 68, Issue 6, June 1982, Page 883, https://doi.org/10.1093/jnci/68.6.883 Published: 01 June 1982
Case 16-1978
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Kenneth A. Arndt, Eugene J. Mark
Journal: New England Journal of Medicine (1978)

Presentation of CaseA 44-year-old man was admitted to the hospital because of diarrhea.The patient was a chronic alcoholic who began to drink at the age of 16 years and had consumed alcohol in large amounts since the age of 25 years. Six months earlier he was seen at another hospital, where peripheral edema was observed, the prothrombin time was prolonged, and tests for occult blood in the stools were intermittently positive. Chlorothiazide and spironolactone were prescribed. Three days before admission diarrhea developed, with nausea, vomiting, sore throat and fever.The patient worked as a fish cutter. There was . . .
Virus of Avian Erythromyeloblastic Leukosis. V. &lt;italic&gt;p&lt;/italic&gt;H Stability of the Virus Particles, the Infectivity and the Enzyme Dephosphorylating Adenosine Triphosphate&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Eckert, Edward A., Green, Irving, Sharp, D. G., Beard, Dorothy, Beard, J. W.
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Virus of Avian Erythromyeloblastic Leukosis. V. pH Stability of the Virus Particles, the Infectivity and the Enzyme Dephosphorylating Adenosine Triphosphate Get access Edward A. Eckert, Edward A. Eckert Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar Irving Green, Irving Green Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar D. G. Sharp, D. G. Sharp Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Beard, Dorothy Beard Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Beard J. W. Beard Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 5, April 1955, Pages 1209–1215, https://doi.org/10.1093/jnci/15.5.1209 Published: 01 April 1955 Article history Received: 13 September 1954 Published: 01 April 1955
Health reforms achieved primary goals, says Obama
Authors: Michael McCarthy
Journal: BMJ (2016)

US president Barack Obama has issued a strong defense of his record on health, saying that the Affordable Care Act (ACA) has achieved its aims of reducing the number of people without health insurance, improving the quality of care, and slowing the growth of healthcare spending.

Writing in the Journal of the American Medical Association , Obama said that when he took office he “had to deal with one of the nation’s most intractable and long standing problems, a healthcare system that fell far short of its potential.”1 One of the impetuses for reform was his “deeply held belief that healthcare is not a privilege for a few, but a right for all.”

Obama said that, despite the act’s success, …
Deutetrabenazine for Treatment of Chorea in Huntington Disease
Authors: Michael D. Geschwind, Nick Paras
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Campagne de vaccination suite à l’augmentation de l’incidence de l’infection à méningocoque du sérogroupe C dans le département du Puy-de-Dôme (France)
Authors: D Lévy-Bruhl, A Perrocheau, M Mora, M K Taha, S Dromell-Chabrier, I Quatresous
Journal: Eurosurveillance (2002)

Dans le departement francais du Puy-de-Dome, 17 cas d’infections invasives a meningocoque C ont ete declares entre mars 2001 et la premiere semaine de janvier 2002. Sur les 15 cas confirmes, 11 (73%) etaient du serogroupe C, 2 cas (13%) du serogroupe B et 2 n’ont pu etre identifies. L’augmentation rapide des cas sur une periode de faible endemicite dans le reste du territoire, et leur severite (letalite 27%, purpura fulminans 64%) ont conduit les autorites sanitaires a mener une campagne de vaccination ciblant les enfants et les jeunes adultes de 2 mois a 20 ans residant dans une partie limitee du departement. Environ 80 000 personnes ont ete vaccinees entre le 16 janvier et le 9 fevrier 2002. Sur les 1390 effets secondaires notifies, plus de la moitie etait des migraines ou des vertiges. A la mi-mars, aucun nouveau cas de meningite n’a ete declare depuis le 6 janvier 2002.
Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer
Authors: Fei Xing, Yin Liu, Sambad Sharma, Kerui Wu, Michael D. Chan, Hui-Wen Lo, Richard L. Carpenter, Linda J. Metheny-Barlow, Xiaobo Zhou, Shadi A. Qasem, Boris Pasche, Kounosuke Watabe
Journal: Cancer Research (2016)

Abstract Brain metastasis is one of the chief causes of mortality in breast cancer patients, but the mechanisms that drive this process remain poorly understood. Here, we report that brain metastatic cells expressing high levels of c-Met promote the metastatic process via inflammatory cytokine upregulation and vascular reprogramming. Activated c-Met signaling promoted adhesion of tumor cells to brain endothelial cells and enhanced neovascularization by inducing the secretion of IL8 and CXCL1. Additionally, stimulation of IL1β secretion by activation of c-Met induced tumor-associated astrocytes to secrete the c-Met ligand HGF. Thus, a feed-forward mechanism of cytokine release initiated and sustained by c-Met fed a vicious cycle that generated a favorable microenvironment for metastatic cells. Reinforcing our results, we found that pterostilbene, a compound that penetrates the blood–brain barrier, could suppress brain metastasis by targeting c-Met signaling. These findings suggest a potential utility of this natural compound for chemoprevention. Cancer Res; 76(17); 4970–80. ©2016 AACR.
Zinc finger protein 191 inhibits hepatocellular carcinoma metastasis through discs large 1‐mediated yes‐associated protein inactivation
Authors: Di Wu, Guoyuan Liu, Yufeng Liu, Hexige Saiyin, Chenji Wang, Zhen Wei, Wenjiao Zen, Danyang Liu, Qi Chen, Zhonghua Zhao, Liping Zou, Haojie Huang, Songmin Jiang, Long Yu
Journal: Hepatology (2016)

Interplay between cell polarity module Scribble‐Lethal Giant Larvae‐Discs Large 1 (DLG1) and Yes‐associated protein (YAP) appears critical in tumor metastasis. We identified zinc finger protein 191 (ZNF191) as a metastasis suppressor acting through DLG‐YAP crosstalk in hepatocellular carcinoma (HCC). Overexpression of ZNF191 in HCC cells impaired cell motility, while ZNF191 depletion promoted cell migration in vitro and metastasis in vivo through triggering YAP signaling. Chromatin immunoprecipitation‐sequencing revealed that ZNF191 specifically bound to the promoter of DLG1, a cell polarity maintainer and a negative regulator of YAP. The binding sequence of ZNF191 at the DLG1 promoter is a seven‐repeat of TCAT motif. Double‐knockdown experiments inferred that DLG1 was not only the mediator of the function of ZNF191 to suppress migration but also a link between ZNF191 and YAP signaling. Decreased expression of ZNF191 in human metastatic HCC specimens correlated positively with DLG1 levels but inversely with YAP activation. Our findings illustrate a YAP‐targeting, antimetastasis function of ZNF191, thereby representing a possible prognostic marker and a potential target for metastasis therapy. Conclusion: ZNF191 directly binds to the DLG1 promoter at a typical TCAT repeating motif and activates the expression of DLG1; through up‐regulating DLG1, ZNF191 inhibits cell migration and YAP activation in HCC cells and eventually inhibits metastasis . (H epatology 2016;64:1148‐1162)
Antineoplastic Agents Derived From the Periwinkle Plant
Authors: K L BROWN
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Controversy in medicine and psychiatry
Authors: L M Koran
Journal: American Journal of Psychiatry (1975)

Factual and ethical controversies confront physicians in medicine as well as in psychiatry. If psychiatrists can impart a perspective on these controversies and their growth-stimulating quality to medical students and thereby increase their tolerance for uncertainty, they will aid them in becoming better physicians and will perhaps also remove one reason for their disinterest in psychiatry.
NSAIDs and EGFR Inhibitors for Duodenal Polyp Prevention
Authors: Asad Umar, Ellen Richmond
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal